Status:
RECRUITING
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
Lead Sponsor:
Krystal Biotech, Inc.
Conditions:
Cancer
Melanoma Stage III
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
KB707-01 is a Phase 1/2, open-label, multicenter, dose escalation and expansion study. The study will evaluate the safety and tolerability of KB707 in adults with locally advanced or metastatic solid ...
Detailed Description
KB707 is a genetically modified herpes simplex type 1 virus that is designed to stimulate an anti-tumor immune response through the production of cytokines. This is a first-in-human (FIH) clinical stu...
Eligibility Criteria
Inclusion
- Key
- Life expectancy \>12 weeks
- ECOG performance status of 0 or 1
- Have measurable disease per RECIST v1.1 at Screening
- Cohorts 1-4 only: Histologically confirmed diagnosis of a locally advanced or metastatic solid tumor and the individual has progressed on standard of care therapy, cannot tolerate standard of care therapy, refused standard of care therapy, or there is no standard of care therapy.
- Cohorts 5 and 6 only: Histologically confirmed stage III (unresectable) or stage IV melanoma, as per American Joint Committee on Cancer (AJCC) staging system (8th edition; AJCC 2017) and
- Subject has previously failed one prior anti-PD-1/PD-L1 treatment (as monotherapy or in combination with other checkpoint inhibitors such as anti-LAG-3 or anti-CTLA-4); and
- If proto-oncogene B-Raf (BRAF) V600 mutation-positive, subject previously failed a BRAF inhibitor or BRAF inhibitor in combination with mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor
- Cohort 5 only: Age 12 years or older at the time of informed consent
- Cohort 6 only: Age 18 years or older at the time of informed consent
- Key
Exclusion
- Prior surgery or radiation therapy must be fully recovered, including all radiation -related toxicities and subject does not require systemic corticosteroids
- The subject is pregnant, nursing, or plans to become pregnant during study treatment and through three months after the last dose of KB707
- Have known history of positive human immunodeficiency virus (HIV 1/2)
- Cohorts 5 and 6 only:
- Subject has a known additional malignancy that is progressing or requires active treatment.
- Subject has uveal/ocular melanoma.
- The subject has active brain metastases or leptomeningeal metastases
- Subject has received more than 2 lines of systemic therapy for unresectable or metastatic melanoma
- Prior anti-LAG-3 and/or anti-PD-1 therapy was intolerable and required discontinuation of treatment
Key Trial Info
Start Date :
October 31 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2027
Estimated Enrollment :
240 Patients enrolled
Trial Details
Trial ID
NCT05970497
Start Date
October 31 2023
End Date
July 1 2027
Last Update
May 18 2025
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
UCLA Health
Los Angeles, California, United States, 90095
2
Mission Dermatology Center
Rancho Santa Margarita, California, United States, 92688
3
BRCR Global
Weston, Florida, United States, 33326
4
IU Simon Comprehensive Cancer Center
Indianapolis, Indiana, United States, 46202